The Cancer Research Institute (CRI) will host its 22nd Annual International Cancer Immunotherapy Symposium October 6-8, 2014 at The Grand Hyatt in New York City. Attracting clinicians, laboratory scientists, postdoctoral fellows, and graduate students, the symposium will feature plenary presentations from leaders in immunology and cancer immunotherapy, a poster session, and numerous networking opportunities.
This year’s CRI symposium, entitled Cancer Immunotherapy: Out of the Gate, will harness the excitement and enthusiasm generated by recent clinical successes to explore new and emerging areas of basic, translational, and clinical research. Topics such as the use of genomic methods to catalogue cancer heterogeneity, mechanistic studies of checkpoint blockage antibodies, new views on immunosurveillance and immunoregulation, and emerging therapies that are altering the landscape of cancer treatment will be discussed. Come hear the latest developments from the scientists who are leading the charge.
New This Year: CIC Satellite Meeting
New to the meeting this year, we will be hosting a special Cancer Immunotherapy Consortium (CIC) satellite meeting on October 5 entitled Development of Surrogate Endpoints for Cancer Immunotherapy Trials. The meeting will consist of a full day of presentations and panel discussions addressing the key rationale, challenges, and solutions surrounding the development of surrogate endpoints for cancer immunotherapy. This meeting will represent the culmination of a CIC-led community-wide effort that brings together the major stakeholders in the field, including experts from industry, academia, and regulatory bodies as well as patients. The output of the meeting will be a consensus-driven roadmap for the efficient regulatory approval of future immunotherapies.
Please note, separate registration for the CIC Satellite Meeting is required. Attendance is complimentary for 2014 CRI Symposium registrants, but space is limited. Registration fees will apply for those not attending the symposium. More information. For more information, click here.
Cancer Immunotherapy 2014 Planning Committee
James P. Allison, The University of Texas MD Anderson Cancer Center
Glenn Dranoff, Dana-Farber Cancer Institute
Carl F. Nathan, Weill Cornell Medical College
Ellen Puré, University of Pennsylvania School of Veterinary Medicine
Robert D. Schreiber, Washington University School of Medicine
Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center